The University of Oslo , formerly The Royal Frederick University , is the oldest and largest university in Norway, located in the Norwegian capital of Oslo. The university is recognized as one of Northern Europe's most prestigious universities. The Academic Ranking of World Universities has ranked it the 67th best university in the world.The university has approximately 27,700 students and employs around 6,000 people. Its faculties include Theology , Law, Medicine, Humanities, Mathematics, natural science, social science, Dentistry, and Education. The university's original neoclassical campus is located in the centre of Oslo; it is currently occupied by the Faculty of Law. Most of the university's other faculties are located at the newer Blindern campus in the suburban West End. The Faculty of Medicine is split between several university hospitals in the Oslo area.The university was founded in 1811 and was modelled after the University of Copenhagen and the recently established University of Berlin. It was originally named for King Frederick VI of Denmark and Norway, and received its current name in 1939. The university is informally also known as Universitetet , having been the only university in Norway until 1946, and was commonly referred to as "The Royal Frederick's" prior to the name change.The University of Oslo is home to five Nobel Prize winners. The Nobel Peace Prize was awarded in the university's Atrium from 1947 to 1989. Since 2003, the Abel Prize is awarded in the Atrium. Wikipedia.
NewSouth Innovations Pty Ltd and University of Oslo | Date: 2016-12-06
The invention generally relates to the field of saxitoxins and the identification of microorganisms capable of producing them. More specifically, the invention relates to the identification of genes encoding saxitoxin in dinoflagellates, and methods for the specific detection of dinoflagellates that are producers of saxitoxins.
Nordlandssykehuset Hf, Norwegian University of Science, Technology and University of Oslo | Date: 2014-03-21
The present invention relates to chimeric anti-CD14 antibodies and methods of using the same. In some embodiments, the present invention relates to the use of chimieric anti-CD 14 antibodies in research, diagnostic, and therapeutic applications. In one embodiment, the anti-CD14 antibody has a variable light chain of SEQ ID NO: 1 and a variable heavy chain of SEQ ID NO: 2 (isolated from the hybridoma clone 18D11). In another embodiment, the anti-CD14 antibody has a variable light chain of SEQ ID NO: 3 and a variable heavy chain of SEQ ID NO: 4 (isolated from the hybridoma clone Mil2).
University of Oslo | Date: 2015-06-10
The present invention relates to peptides presented on the cell surface of cells in the MHC class I (MHC I) context in which the invariant chain has been engineered to favor loading of specific antigens and generate CD8+ T-cell activation
University of Oslo | Date: 2017-03-08
The present invention relates to compositions and method for differentiating stem ceils. In particular, the present invention relates to methods of generating hepatocytes from human pluripotent stem cells (hPSCs) using a small molecule-driven approach.
Rottingen J.A.,University of Oslo
Lancet | Year: 2013
The need to align investments in health research and development (R&D) with public health demands is one of the most pressing global public health challenges. We aim to provide a comprehensive description of available data sources, propose a set of indicators for monitoring the global landscape of health R&D, and present a sample of country indicators on research inputs (investments), processes (clinical trials), and outputs (publications), based on data from international databases. Total global investments in health R&D (both public and private sector) in 2009 reached US$240 billion. Of the US$214 billion invested in high-income countries, 60% of health R&D investments came from the business sector, 30% from the public sector, and about 10% from other sources (including private non-profit organisations). Only about 1% of all health R&D investments were allocated to neglected diseases in 2010. Diseases of relevance to high-income countries were investigated in clinical trials seven-to-eight-times more often than were diseases whose burden lies mainly in low-income and middle-income countries. This report confirms that substantial gaps in the global landscape of health R&D remain, especially for and in low-income and middle-income countries. Too few investments are targeted towards the health needs of these countries. Better data are needed to improve priority setting and coordination for health R&D, ultimately to ensure that resources are allocated to diseases and regions where they are needed the most. The establishment of a global observatory on health R&D, which is being discussed at WHO, could address the absence of a comprehensive and sustainable mechanism for regular global monitoring of health R&D. Copyright © 2013 Elsevier Ltd. All rights reserved.
Agency: European Commission | Branch: H2020 | Program: SGA-RIA | Phase: FETFLAGSHIP | Award Amount: 89.00M | Year: 2016
Understanding the human brain is one of the greatest scientific challenges of our time. Such an understanding can provide profound insights into our humanity, leading to fundamentally new computing technologies, and transforming the diagnosis and treatment of brain disorders. Modern ICT brings this prospect within reach. The HBP Flagship Initiative (HBP) thus proposes a unique strategy that uses ICT to integrate neuroscience data from around the world, to develop a unified multi-level understanding of the brain and diseases, and ultimately to emulate its computational capabilities. The goal is to catalyze a global collaborative effort. During the HBPs first Specific Grant Agreement (SGA1), the HBP Core Project will outline the basis for building and operating a tightly integrated Research Infrastructure, providing HBP researchers and the scientific Community with unique resources and capabilities. Partnering Projects will enable independent research groups to expand the capabilities of the HBP Platforms, in order to use them to address otherwise intractable problems in neuroscience, computing and medicine in the future. In addition, collaborations with other national, European and international initiatives will create synergies, maximizing returns on research investment. SGA1 covers the detailed steps that will be taken to move the HBP closer to achieving its ambitious Flagship Objectives.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SC1-PM-04-2016 | Award Amount: 10.77M | Year: 2017
Our main objective is to identify determinants of brain, cognitive and mental health at different stages of life. By integration, harmonisation and enrichment of major European neuroimaging studies of age differences and changes, we will obtain an unparalleled database of fine-grained brain, cognitive and mental health measures of more than 6.000 individuals. Longitudinal brain imaging, genetic and health data are available for a major part, as well as cognitive/mental health measures for extensively broader cohorts, exceeding 40.000 examinations in total. By linking these data, also to additional databases and biobanks, including birth registries, national and regional archives, and by enriching them with new online data collection and novel measures, we will address risk and protective factors of brain, cognitive and mental health throughout the lifespan. We will identify the pathways through which risk and protective factors work and their moderators. Through exploitation of, and synergies with, existing European infrastructures and initiatives, this approach of integrating, harmonising and enriching brain imaging datasets will make major conceptual, methodological and analytical contributions towards large integrative cohorts and their efficient exploitation. We will thus provide novel information on brain, cognitive and mental health maintenance, onset and course of brain, cognitive and mental disorders, and lay a foundation for earlier diagnosis of brain disorders, aberrant development and decline of brain, cognitive and mental health, as well as future preventive and therapeutic strategies. Working with stakeholders and health authorities, the project will provide the evidence base for policy strategies for prevention and intervention, improving clinical practice and public health policy for brain, cognitive and mental health. This project is realized by a close collaboration of small and medium-sized enterprise (SME) and major European brain research centres
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SC1-PM-01-2016 | Award Amount: 15.04M | Year: 2017
The complex interactions between genetic and non-genetic factors produce heterogeneities in patients as reflected in the diversity of pathophysiology, clinical manifestations, response to therapies, disease development and progression. Yet, the full potential of personalized medicine entails biomarker-guided delivery of efficient therapies in stratified patient populations. MultipleMS will therefore develop, validate, and exploit methods for patient stratification in Multiple Sclerosis, a chronic inflammatory disease and a leading causes of non-traumatic disability in young adults, with an estimated cost of 37 000 per patient per year over a duration of 30 years. Here we benefit from several large clinical cohorts with multiple data types, including genetic and lifestyle information. This in combination with publically available multi-omics maps enables us to identify biomarkers of the clinical course and the response to existing therapies in a real-world setting, and to gain in-depth knowledge of distinct pathogenic pathways setting the stage for development of new interventions. To create strategic global synergies, MultipleMS includes 21 partners and covers not only the necessary clinical, biological, and computational expertise, but also includes six industry partners ensuring dissemination and exploitation of the methods and clinical decision support system. Moreover, the pharmaceutical industry partners provide expertise to ensure optimal selection and validation of clinically relevant biomarkers and new targets. Our conceptual personalized approach can readily be adapted to other immune-mediated diseases with a complex gene-lifestyle background and broad clinical spectrum with heterogeneity in treatment response. MultipleMS therefore goes significantly beyond current state-of-the-art thereby broadly affecting European policies, healthcare systems, innovation in translating big data and basic research into evidence-based personalized clinical applications.
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: INFRADEV-02-2016 | Award Amount: 9.05M | Year: 2017
The European Solar Telescope (EST) will be a revolutionary Research Infrastructure that will play a major role in answering key questions in modern Solar Physics. This 4-meter class solar telescope, to be located in the Canary Islands, will provide solar physicists with the most advanced state-of-the-art observing tools to transform our understanding of the complex phenomena that drive the solar magnetic activity. The principal objective of the present Preparatory Phase is to provide both the EST international consortium and the funding agencies with a detailed plan regarding the implementation of EST. The specific objectives of the proposed preparatory phase are: (1) to explore possible legal frameworks and related governance schemes that can be used by agencies to jointly establish, construct and operate EST as a new research infrastructure, with the implementation of an intermediate temporary organisational structure, as a previous step for future phases of the project; (2) to explore funding schemes and funding sources for EST, including a proposal of financial models to make possible the combination of direct financial and in-kind contributions towards the construction and operation of EST; (3) to compare the two possible sites for EST in the Canary Islands Astronomical Observatories and prepare final site agreements; (4) to engage funding agencies and policy makers for a long-term commitment which guarantees the construction and operation phases of the Telescope; (5) to involve industry in the design of EST key elements to the required level of definition and validation for their final production; (6) to enhance and intensify outreach activities and strategic links with national agencies and the user communities of EST. To accomplish the aforementioned goals, this 4-year project, promoted by the European Association for Solar Telescopes (EAST) and the PRE-EST consortium, encompassing 23 research institutions from 16 countries, will set up the Project Office
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: REV-INEQUAL-06-2016 | Award Amount: 5.00M | Year: 2017
ISOTIS addresses the nature, causes and impact of early emerging social and educational inequalities in the context of socioeconomic, cultural and institutional processes. The aim is to contribute to effective policy and practice development to combat inequalities. Quasi-panels and pooled longitudinal datasets will be used to examine the variation in early educational gaps and developmental trajectories across countries, systems and time. To disentangle the complex interactions between characteristics of systems and target groups, ISOTIS will study significant immigrant, indigenous ethnic-cultural and low-income native groups, associated with persistent educational disadvantages. ISOTIS will examine current resources, experiences, aspirations, needs and well-being of children and parents in these groups in the context of acculturation and integration, and in relation to local and national policies. ISOTIS aims to contribute to effective policy and practice development by generating recommendations and concrete tools for (1) supporting disadvantaged families and communities in using their own cultural and linguistic resources to create safe and stimulating home environments for their children; for (2) creating effective and inclusive pedagogies in early childhood education and care centres and primary schools; for (3) professionalization of staff, centres and schools to improve quality and inclusiveness; for (4) establishing inter-agency coordination of support services to children and families; and for (5) developing policies to combat educational inequalities. ISOTIS will develop inter-linked programmes for parents, classrooms and professionals using Virtual Learning Environments for working in linguistically diverse contexts. All this work together is expected to support the education practice and policy field in Europe in meeting the challenges of reducing social and educational inequalities.